Induction of Immune-Stimulating Factors and Oncolysis Upon p14^ARF Gene Transfer in Melanoma Cell Lines

Area of Science:

• Oncology
• Gene Therapy
• Immunology

Background:

• Oncolysis using viral vectors combines gene transfer and host immunity for cancer elimination.
• Recombinant adenoviral vectors are explored for delivering therapeutic genes in cancer treatment.

Purpose of the Study:

• To investigate oncolysis induced by p14^ARF and interferon-β (hIFNβ) gene transfer in human melanoma cells.
• To reveal the role of p14^ARF in promoting immune stimulation and its impact on melanoma treatment.

Main Methods:

• Utilized nonreplicating adenoviral vectors for p14^ARF and hIFNβ gene transfer in human melanoma cell lines (UACC-62 and SK-Mel-29).
• Evaluated oncolysis in vitro and in situ tumor progression in nude mice.
• Assessed the induction of immunogenic cell death factors and pro-immune genes (IRF1, IRF7, IRF9, ISG15, TAP-1, B2M).

Main Results:

• p14^ARF gene transfer induced oncolysis in UACC-62 (p53 wild-type) cells.
• The combination of p14^ARF and hIFNβ benefitted SK-Mel-29 (p53-mutant) cells.
• In situ gene therapy with p14^ARF and hIFNβ reduced tumor progression in UACC-62 xenografts.
• p14^ARF induced immunogenic cell death factors and pro-immune genes in UACC-62 cells, with a partial effect in SK-Mel-29 cells.
• hIFNβ induced immune-stimulating genes in both cell lines.

Conclusions:

• p14^ARF gene transfer can induce oncolysis and immune stimulation in melanoma, suggesting a dual mechanism for cancer therapy.
• The findings advance melanoma gene therapy strategies by highlighting the potential of p14^ARF in enhancing anti-tumor immune responses.